SRZN Surrozen, Inc./DE
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1824893 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY192.1%
TTM net income YoY-349.0%
TTM EPS YoY-138.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-485.4%
Net margin-3,706.4%
FCF margin-292.3%
EBITDA margin-483.4%
Returns
ROE—
ROA-384.3%
ROIC (approx.)—
Asset turnover0.10x
Leverage & solvency
Liabilities / assets407.8%
Debt / equity—
Current ratio7.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-354.2%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.48M | $10.65M |
| R&D expense | $29.36M | $21.13M |
| SG&A expense | $16.20M | $15.06M |
| Operating income | -$42.09M | -$25.54M |
| Pretax income | -$242.03M | -$63.56M |
| Income tax | $0 | $0 |
| Net income | -$242.03M | -$63.56M |
| EBITDA | -$41.55M | -$24.10M |
| EPS (basic) | -32.37 | -21.67 |
| EPS (diluted) | -32.37 | -21.67 |
| Weighted avg. shares (diluted) | 7,478 | 2,933 |
| Balance sheet | ||
| Cash & equivalents | $89.25M | $35.25M |
| Receivables | $0 | $2.04M |
| Current assets | $91.56M | $38.93M |
| PP&E, net | $433,000 | $562,000 |
| Total assets | $98.73M | $48.47M |
| Current liabilities | $9.93M | $7.32M |
| Total liabilities | $286.49M | $69.85M |
| Shareholders' equity | -$187.76M | -$21.38M |
| Shares outstanding | 9.78M | 3.26M |
| Cash flow statement | ||
| Operating cash flow | -$30.24M | -$17.63M |
| Capital expenditure | $128,000 | $26,000 |
| Free cash flow | -$30.37M | -$17.65M |
| Investing cash flow | -$128,000 | -$26,000 |
| Financing cash flow | $85.05M | $16.18M |
| Depreciation & amortization | $537,000 | $1.44M |
| Stock-based compensation | $3.83M | $4.11M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.